SRNE - 17 Reasons to Be Excited About Sorrento Therapeutics and 1 Big Reason to Be Very Worried
At the beginning of this year, Sorrento Therapeutics (NASDAQ: SRNE) was focused on its pain management drug, resiniferatoxin, as well as its Dimeric Antigen Receptor-T (DAR-T) cell therapy targeting various blood cancers and solid tumors.
But the biotech has made a major pivot into therapies, vaccines, and tests for the novel coronavirus that causes COVID-19.
Sorrento's shift into COVID-19 has been quite extensive, including:
For further details see:
17 Reasons to Be Excited About Sorrento Therapeutics and 1 Big Reason to Be Very Worried